LONDON - Arrow Therapeutics Ltd. landed its first deal, licensing A-60444, a small-molecule inhibitor of respiratory syncytial virus, to Novartis Pharma AG for a $10 million down payment and $217 million linked to development milestones, followed by royalties. (BioWorld Today)